Stock listing

NASDAQ:MDGL Madrigal Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Madrigal Pharmaceuticals, Inc.

Follow Madrigal Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:MDGL

$449.74 USD -10.07 (-2.2%)

Close on Oct 16, 2026

Since Jul 6, 2026 -15.1% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$446.61 – $462.07 USDOct 16, 2026
Volume
364,530 sharesOct 16, 2026
Market value
$10.39B USDAt the close on Oct 16, 2026 · price × 23.10M shares outstanding
Madrigal Pharmaceuticals, Inc. logo
Ticker
NASDAQ:MDGL
Asset type
Stock
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Madrigal Pharmaceuticals (NASDAQ:MDGL) Q2 2026 Earnings Call

    Thu, Jul 30, 2026 · 8:00 AM ET

    Watch Transcript

  • Madrigal Pharmaceuticals (NASDAQ:MDGL) Q1 2026 Earnings Call

    Wed, May 06, 2026 · 8:00 AM ET

    Watch Transcript

  • Madrigal Pharmaceuticals (NASDAQ:MDGL) Q4 2025 Earnings Call

    Thu, Feb 19, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Oct 15, 2026

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants

Oct 6, 2026

Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference

Sep 2, 2026

Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors

Aug 12, 2026

Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates

Jul 30, 2026

Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026

Jul 16, 2026

Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio

Jul 13, 2026

Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026

Jun 3, 2026

Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH

May 27, 2026

Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk

May 20, 2026

All Madrigal Pharmaceuticals, Inc. news

Decks

Madrigal Pharmaceuticals, Inc. on 6ix

News releases
26 in the last 12 months · 139 in all · newest Oct 15, 2026 · oldest 2019
Calls
11 calls with a replay · 11 with a transcript · latest Jul 30, 2026
Decks
8 decks · latest Jul 30, 2026

Where Madrigal Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:MDGL · Home listing · This pageNASDAQUnited StatesUSD
LS Exchange:A2APCZLS ExchangeGermanyEUR
gettex:YDO1gettexGermanyEUR
Tradegate:YDO1TradegateGermanyEUR
Lang & Schwarz:A2APCZLang & SchwarzGermanyEUR
LSE:0JXILSEUnited KingdomUSD
BOATS:MDGLBOATSUnited StatesUSD
Milan:1MDGLMilanItalyEUR
Frankfurt:YDO1FrankfurtGermanyEUR
BX Swiss:YDO1BX SwissSwitzerlandCHF
Dusseldorf:YDO1DusseldorfGermanyEUR
Hamburg:YDO1HamburgGermanyEUR
Munich:YDO1MunichGermanyEUR
Stuttgart:YDO1StuttgartGermanyEUR
Hanover:YDO1HanoverGermanyEUR
Xetra:YDO1XetraGermanyEUR

Log in to ask 6ix AI your own questions about Madrigal Pharmaceuticals, Inc.